Thesis (PhD)--University of South Australia, 2000

Electrospinning has the capacity to create fibers of natural or synthetic polymers with dimensions that are similar to analogous fibers in native tissue. Mats consisting of fibers of these sub-micron dimensions have shown promise in provoking little immune response and in offering a habitable environment for cell proliferation. Fibrinogen is a natural protein capable of being electrospun and offers the benefit of existing as part of the natural coagulation cascade. Mats of fibrinogen could be utilized as possible hemostatic dressings or as an early scaffold for cell migration for either wound repair or tissue engineering. The addition of antibiotic into such a dressing/scaffold could prevent infection during healing/incorporation. The goal of this study was to determine any effect that the addition of the antibiotic tetracycline hydrochloride (0%, 2.5%, 5%, 10% by weight) would have on the mechanical properties of electrospun fibrinogen (110 mg/mL, 120 mg/mL, and 130 mg/mL concentrations). Also, the time release of tetracycline from electrospun fibrinogen was investigated. The results show no significant effect of tetracycline loading on the mechanical properties of electrospun fibrinogen under the conditions of this study. The results of the release study demonstrate that initial tetracycline release is dependent upon loading percentage. The release data also demonstrate that the amount of tetracycline released is approximately 20-30% of the tetracycline in the original solution and that the release occurs within approximately 4 hours, with no significant release thereafter. This study demonstrates the feasibility of tetracycline in electrospun fibrinogen for the purposes of short term drug release in fibrinogen-based technologies.

Thesis (M.Med.Sc.) -- University of Adelaide, Dept. of Clinical and Experimental Pharmacology, 2000. / Bibliography: leaves 115-125.

Thesis (MTech(Medical Technology))--Cape Technikon, 1997 / Cryoprecipitates are used as the raw material for the preparation of Factor VIII (FVIIIl) for replacement therapy for haemophiliacs. Routinely, cryoprecipitate only recovers 50% of the Factor VIII in the plasma. The purpose of this study, production of cryoprecipitate, was to investigate those variables which play a key role in determining the yield of Factor VIII present in cryoprecipitate. Cryoprecipitate production involves a wide range of variables which could effect the final outcome of the product. These vary from the donor blood group, time of donation, exercise levels of the donor, to a time delay prior to processing, temperature storage conditions, to the method utilised for plasma freezing and thawing. The objective was to explore which combination of variables in the procedure would lead to a process which would optimize the preparation of cryoprecipitate in a routine environment, to yield the highest levels of Factor VIII. Frequently in scientific investigations, particularly when a practical approach has to be adopted, questions arise in which the effects of a number of different variables in a process, require evaluation. Such questions can usually be most economically investigated, by arranging the analysis according to an ordered plan in which all the factors are viewed in a regular way. Provided the plan has been correctly chosen, it is possible to determine not only the effect of each individual variable, but also the way in which each effect depends on the other factor, by means of an interaction. This makes it possible to obtain a more complete picture of what is happening, than would have been obtained by varying each of the variables one at a time while keeping the others constant. Designs of this sort lend themselves well to statistical analysis, and provide their own estimates of experimental error. This type of statistical analysis called, 2K Fractional Factorial Experimental Design, forms the basis of this study in which 14 key variables in the production process of cryoprecipitate were defined as possible areas in which Factor VIII levels in the cryoprecipitate are effected. Key variables have been identified on an individual basis in previous studies (Burka et al., 1975), however this blended approach to optimise the key variables within the production environment, and define further combinations which could be incorporated into the production, has never been attempted. The statistical design used in the study was compiled by the Institute for Biostatistics of the Medical Research Council (MRC). Units of blood were collected and processed, from blood donors under the stipulated criteria, corresponding to the study design.

Factor VIII, a component of the intrinsic pathway of blood coagulation, has yet to be purified to homogeneity. It appears that, in vivo, the factor VIII coagulant protein is closely associated with one or more other proteins (factor VHI-related antigen and platelet aggregating factor). The material normally isolated from bovine plasma as 'factor VIII' possesses all three activities and is therefore either a mixture or a complex of the various proteins. In the present study, bovine factor VIII:C was purified approximately fivethousand- fold by a combination of ion-exchange chromatography and fractional precipitation. The factor VIII coagulant activity can be separated from the other activities of the 'factor VIII complex' but the procedures involved are not suitable for preparative use as the factor VIII:C which is obtained is unstable. During coagulation, factor VIII:C is required during the activation of factor X. Studies with purified bovine clotting factors indicate that factor IX_a is the enzyme responsible for the cleavage of factor X, in a calcium-dependent reaction which is stimulated by phospholipid. Factor VIII:C further accelerates the rate at which factor X_a is generated. Preliminary investigations of the kinetic parameters of the reaction indicate that the stimulation by factor VIII:C occurs through a marked increase in the V_max of the reaction; factor VIII:C does not affect the K_m for factor X. The coagulant activity of factor VIII is enhanced by exposure to thrombin, but the 'activated' factor VIII:C which is produced is not itself capable of activating factor X in the absence of factor IX_a. Thus, the 'activation' of factor VIII:C, in contrast to the activation of, for example, factors IX and X, does not appear to result in the formation of an enzyme. That is, factor VIII:C is a non-enzymic, high molecular weight cofactor for factor IX_a.

The role of the nonionic surfactant Tween 80 on the behavior of the therapeutic recombinant protein Factor VIII (rFVIII) was investigated at solid/liquid and air/water interfaces. In order to provide a model system to compare results obtained for the complicated rFVIII-Tween system, a well-characterized globular protein lysozyme was used. The experimental scheme involved the introduction of the protein and Tween to the adsorption substrate in different manners, either lysozyme Tween together or in sequence as lysozyme followed by Tween or vice versa. It was observed that the addition of Tween together with lysozyme reduced the amounts adsorbed at hydrophobic surfaces, while no such reduction was observed on hydrophilic surfaces. A high Tween concentration was required to effect the removal of the lysozyme molecules from the hydrophobic surface and Tween was not effective in removing lysozyme from the hydrophilic surface at any concentration. These results suggest that the Tween-surface interaction is important in determining lysozyme adsorption. Similar observations were made for the rFVIII-Tween system at hydrophobic and hydrophilic silica interfaces. In this case, the presence of interfacial and solution Tween together resulted in complete prevention of rFVIII adsorption. Electrostatic forces were observed to be play an important role in rFVIII adsorption. The rFVIII-Tween interactions at solid interfaces were also evaluated using intrinsic fluorescence and biological activity measurements. Results obtained with respect rFVIII adsorbed mass, and structure or biological activity change upon adsorption, were evaluated in parallel. This parallel evaluation suggested that rFVIII adsorption on hydrophilic, negatively charged surfaces is likely to be highly ordered and oriented in a manner that retains the solvent accessibility of the active sites in rFVIII. On the other hand, rFVIII may adsorb to hydrophobic surfaces in different orientations, with a likelihood of surface induced unfolding. rFVIII-Tween interaction at the air/water interface was investigated separately. Surface tension data recorded for rFVIII-Tween mixtures suggested that Tween dominated the air/water interface as the Tween concentration was increased. Reduced interface-induced unfolding was observed at high Tween concentrations. These results were also thought to contribute to the reduction in rFVIII aggregation typically observed as a result of exposure to the air/water interface. / Graduation date: 2006

Des résultats d’expériences cliniques de reconstruction de l’os maxillaire faites à partir de la greffe d’une "pâte osseuse" gélifiée par l’ajout de facteur tissulaire ont été le primum movens de ce travail. Cette "pâte osseuse", faite d’os en poudre et de plasma enrichi en plaquette (PRP) à laquelle on ajoute du facteur tissulaire, est un modèle à la fois de la coagulation et de la régénération osseuse. Pour analyser des effets de la coagulation, nous avons utilisé un modèle connu : la culture primaire de cellules endothéliales (HUVEC). Les effets in vitro des facteurs de coagulation, dénommés protéases de la coagulation, pris séparément, ont été bien étudiés dans ces cellules, néanmoins aucune information sur l’effet combiné de ces protéases ou du plasma en coagulation n’était connue. Nous avons mesuré la "signalisation calcium" comme réponse cellulaire aux différents agents et ces mesures de la signalisation calcium ont été complétées par la mesure d’une autre réponse biologique, à savoir la sécrétion de cytokines pro-inflammatoires (IL-6 et IL-8). Pour l’étude de la régénération osseuse, la signalisation calcium a été mesurée sur une lignée d’ostéosarcomes humains (SaOS-2), stimulée par des protéases de la voie extrinsèque de la coagulation (facteur VIIa, facteur Xa et thrombine). Comme réponse biologique complémentaire, nous avons évalué l’effet des protéases d’intérêt sur l’apoptose induite par l’absence de sérum dans le milieu de culture. Les premiers travaux, réalisés sur les HUVEC, nous ont permis de montrer que le facteur Xa et la thrombine induisaient des signaux calcium différents sur ces cellules en mono couches, alors que le complexe facteur tissulaire – facteur VIIa ne provoquait aucune signalisation calcium. Nous avons également pu montrer une addition des signaux calcium induits par le facteur Xa et la thrombine. L’activation in situ du facteur Xa et de la thrombine à partir de leur zymogène a permis à la fois de confirmer les résultats précédents et de se rapprocher de l’in vivo. Finalement, au plus proche de l’in vivo, les expériences faites avec du plasma en coagulation ont également permis de détecter un signal calcium. La réponse biologique (sécrétion d’IL-6 et d’IL-8) en aval du signal calcium a confirmé les résultats calcium. En ce qui concerne la régénération osseuse étudiée à partir de SaOS-2, nous avons démontré l’expression du facteur tissulaire sur la lignée SaOS-2 et nous avons montré que le facteur VIIa, le facteur Xa et la thrombine induisaient tous des signaux calcium. Ces signaux présentaient des caractéristiques propres suivant la ou les protéase(s) utilisée(s) pour la stimulation. Les mesures ont également permis de caractériser, sur ces cellules, les récepteurs activés par les protéases d’intérêt, à savoir les "protease-activated receptors" 1 et 2 (PAR-1 et PAR-2). Comme réponse biologique, nous avons mesuré la diminution de l’apoptose induite par les protéases en absence de sérum dans le milieu de culture. Il a ainsi été montré que seule l’activation du récepteur PAR-1 permettait de diminuer l’apoptose. Finalement, nous avons caractérisé la voie suivie, qui passait par la phosphoinositide 3-kinase et la voie des MAPK Raf/MEK/ERK 1/2. En conclusion, cette thèse a permis de montrer, d’une part, que le facteur Xa et la thrombine provoquent des réponses calciques et proinflammatoires additifs dans les cellules endothéliales et, d’autre part, que le complexe facteur tissulaire – facteur VIIa, le facteur Xa et la thrombine induisent des signaux calcium caractéristiques dans les ostéosarcomes par l’activation des récepteurs PAR, l’activation de PAR-1 diminuant l’apoptose induite par l’absence de sérum dans le milieu de culture.

Thesis (M.S.)--Oregon State University, 2010. / Printout. Includes bibliographical references (leaves 42-44). Also available on the World Wide Web.

Haemophilia B is a bleeding disorder caused by various mutations of the coagulation Factor IX gene (F9) resulting in qualitative or quantitative Factor IX protein (FIX) deficiency. Factor replacement therapy is the current standard of care. Cure may be possible in the near future by gene therapy — the transfer of normal copies of F9 to patients with haemophilia, causing establishment of FIX production and correction of the bleeding phenotype. Mesenchymal stem cells (MSC) are potential vehicles for gene delivery through ex vivo gene transfer and subsequent transplantation to the patient. Lentiviral vectors can transduce MSC effectively and mediate long term gene expression. However, gene expression may decline with time due to transgene silencing. Ubiquitous Chromatin Opening Element (UCOE) is a set of genetic sequences cloned from housekeeping genes that can maintain a transcriptionally competent, open chromatin structure and was shown to prevent gene silencing by resisting DNA methylation. We tested human F9 expression and FIX protein secretion by transducing MSC with lentiviral vectors that carry the FIX gene under the control of A2UCOE (A2UCOE-hF9). A2UCOE is a 2.2 kb sequence cloned from the HNRPA2B1–CBX3 gene loci that harbour UCOE function. A2UCOE-eGFP, an enhanced Green Fluorescent Protein (eGFP) gene expression construct, was used to assist in vector titration of A2UCOE-hF9 by flow cytometry and quantitative reverse transcription-polymerase chain reaction (qRT-PCR). MSC were transduced at various Multiplicities of Infection (MOIs) by A2UCOE-hF9 lentiviral vector. Upon transduction, F9 mRNA expression and FIX secretion were measured by qRT-PCR and ELISA respectively. Osteogenic and adipogenic differentiation assay were performed to compare differentiation potential before and after transduction at an MOI of 1. F9 mRNA expression and FIX secretion were both undetectable in untransduced MSC. Upon transduction, vector dose-dependent increase in F9 mRNA expression and FIX secretion were detected at MOIs of 1, 2, 4 and 8. The level of secreted FIX ranges from 20 to 150 μIU in 72 hours. Osteogenic and adipogenic differentiation were not affected post-transduction at an MOI of 1. In conclusion, FIX secretion by MSC was detected upon A2UCOE-hF9 lentiviral transduction. However, the level of FIX appeared to be low compared to published studies. Further studies are required to determine the cause of low FIX expression, develop methods to maximize FIX expression and confirm whether A2UCOE can prevent gene silencing and maintain sustainable gene expression. / published_or_final_version / Paediatrics and Adolescent Medicine / Master / Master of Research in Medicine

Les adénovirus (Ad) sont parmi les vecteurs les plus utilisés en thérapie génique. Cependant, les données d’essais pré-Cliniques et cliniques ont montré qu’ils induisaient une forte toxicité hépatique consécutive à leur tropisme hépatique, une réponse inflammatoire et une forte thrombocytopénie. Différents travaux avaient montré que l’interaction de l’Ad avec le facteur de la coagulation X (FX).était responsable de la transduction in vivo des hépatocytes après administration systémique des vecteurs Ad. Cependant, des résultats précédents du laboratoire avaient montré également que le pseudotypage d’une autre protéine de capside, la fibre, permettait de réduire la transduction hépatique. Dans le but de mieux comprendre le rôle de la fibre dans le tropisme et la toxicité des Ad, nous avons comparé des Ad recombinants pseudotypés pour tout (tige et tête de la fibre : AdF3) ou partie (tige : AdS3K5) de la fibre Ad3 avec un Ad5 à capside non modifiée (Adwt). Après administration systémique chez la souris, l’AdF3 et l’AdS3K5 induisent une plus faible expression du transgène dans le foie et la rate comparativement à l’Ad5wt. Cette réduction ne résulte ni d’un défaut de capture de ces vecteurs dans le foie ni de leur incapacité à utiliser le FX. Cependant, nos résultats ont révélé que les Ad pseudotypés par la fibre Ad3 étaient capturés de façon plus importante par les cellules de Kupffer. Nous avons montré que cette capture était une propriété intrinsèque de la fibre Ad3 puisqu’elle était observée également après administration systémique d’un Ad de sérotype 3. De façon intéressante, les Ad pseudotypés par la fibre Ad3 restent capables de transférer des gènes dans les tumeurs aussi efficacement que l’Adwt.Dans la deuxième partie de nos travaux, nous avons cherché à mieux comprendre les mécanismes de la thrombocytopénie consécutive à l’administration d’Ad. Nous avons défini la cinétique de la thrombocytopénie ainsi que l’effet de la dose virale. Nous avons montré que certains facteurs de l’hôte comme les facteurs de la coagulation ou la rate n’étaient pas impliqués dans la thrombocytopénie. De façon intéressante, nous avons montré que la fibre Ad5 jouait un rôle dans l’induction de la baisse plaquettaire puisque l’administration des virus à fibre Ad3 n’induisait plus de forte baisse plaquettaire. Parallèlement, nous avons observé un profil inflammatoire associé à l’administration des Ad à fibre modifiée beaucoup plus réduit que celui de l’Adwt. Nos travaux en cours évaluent l’existence possible d’une corrélation entre la production de cytokines/chimiokines et la thrombocytopénie.L’ensemble de ces résultats montre que le pseudotypage des Ad5 par la fibre de l’Ad3 permet de réduire leur toxicité et de limiter la réponse inflammatoire tout en conservant un transfert de gènes efficace dans les tumeurs. L’introduction de ce type de modification de capside dans les Ad oncolytiques devrait permettre de conserver leur capacité à se répliquer dans les tumeurs tout en limitant les toxicités liées à leur dissémination par voie systémique. / To date adenoviruses (Ad) are the most used vectors in gene therapy. However, Ad use is hampered by a strong liver tropism that leads to hepatotoxicity, a strong inflammatory response and the induction of thrombocytopenia. Binding of Ad hexon to coagulation factor X (FX) is responsible for hepatocyte transduction in vivo. As a consequence, mutation of hexon protein abrogates Ad interaction with FX and reduces liver transduction. However, previous results of our lab have demonstrated that Ad5 pseudotyping with fiber Ad3 also resulted in significant reduction of liver transduction. To understand how fiber modification affects in vivo Ad tropism, we used two pseudotyped viruses with whole (AdF3) or only the shaft (AdS3K5) of Ad3 fiber.Following systemic delivery of fiber-Modified Ads, a reduced transduction was observed 2 days p.i. in liver and spleen. This reduction was not due to the impairment of fiber-Modified Ads liver entry or FX use in vivo. Remarkably, after Kupffer cells depletion, a restored transgene expression level was observed, suggesting that fiber-Modified Ads are strongly uptaken by Kupffer cells. We have demonstrated that this strong uptake is an Ad3 intrinsic property since Ad3 was also strongly uptaken by Kupffer cells. Interestingly, fiber-Modified Ads transduce tumours as efficiently as Ad5. In the second part of this work, we aimed to better understand the mechanism of Ad-Induced thrombocytopenia. We first defined the kinetic and dose-Dependence of Ad-Induced thrombocytopenia. Then, we have shown that factors of the host such as the coagulation factors and the spleen were not involved in the thrombocytopenia development. Interestingly, we demonstrated o role for Ad5 in this platelet count reduction since fiber-Modified Ad induced only a modest thrombocytopenia. In parallel, we have observed a reduced production of inflammatory cytokine and chemokine following fiber-Modified Ad administration. Experiments are ongoing to investigate a possible correlation between inflammatory responses and thrombocytopenia. Altogether, our findings demonstrate that Ad5 pseudotyping with Ad3 fiber allows à reduced toxicity and inflammatory response while tumour transduction efficacy is remained. Therfore, oncolytic Ad pseudotyped with Ad3 fiber might be potent tool in tumor virotherapy while limiting risk of toxicity.